November 13, 2025

‘FDA Said Yes, Despite Inconclusive Evidence’

The FDA’s authorization of the Q-Collar is under scrutiny after researchers identified duplicated data, altered study endpoints, and unsubstantiated “brain protection” claims.

Conexiant

November 10, 2025

FDA Proposes Removal of Box Warnings

The FDA proposed updates to menopausal hormone therapy labeling to reflect current evidence on benefits and risks.

Conexiant

November 06, 2025

‘Wasteful’? Doctors Call It Essential

Proposed cuts to the Hospital Preparedness Program may limit hospitals’ capacity to manage pandemics, natural disasters, and mass-casualty events affecting U.S. health systems.

KFF Health News

November 06, 2025

Lumateperone Approved for Major Depression

The atypical antipsychotic demonstrated statistically significant improvements over placebo in two phase 3 trials, with separation from placebo emerging within 1 to 2 weeks and 65% of patients achieving remission at 6 months.

Conexiant

October 29, 2025

H-1B Visa Changes: Who Pays the Price?

New fee structure could hit hardest where physicians are needed most.

Conexiant

October 20, 2025

Which Hair Loss Treatments Truly Deliver Results?

Researchers compare prescription and over-the-counter treatments for male hair loss to determine which best improve hair density.

Conexiant

October 17, 2025

FDA Awards Nine CNPV Vouchers to Speed Reviews

Pilot aims to expedite access to high‑impact therapies by streamlining FDA review and strengthening sponsor–agency collaboration.

Conexiant

October 16, 2025

HHS Memo: Fringe Finds a Footing

From wheat fields to Washington: a decades-old fear about skies and 'sprays' rises again, colliding with science, social media, and the machinery of federal policymaking.

KFF Health News

October 16, 2025

Depression Risk Rises Among Gabapentin Users

Gabapentin is most strongly associated with depression among women, lower-income patients, and those who sleep fewer than 7 hours per night.

Conexiant